Influence of peripheral artery disease and statin therapy on apolipoprotein profiles

Andrew W. Gardner, Petar Alaupovic, Donald E. Parker, Polly S. Montgomery, Omar L. Esponda, Ana I. Casanegra

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n=17) or untreated (n=12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P<0.05) and lower values of Lp-A-I:A-II (P<0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P<0.05), Lp-A-II:B:C:D:E (P<0.05), Lp-B:E + Lp-B:C:E (P<0.05), Lp-B:C (P<0.05), and Lp-A-I (P<0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670.

Original languageEnglish (US)
Article number548764
JournalInternational Journal of Vascular Medicine
Volume2013
DOIs
StatePublished - Jan 1 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Apolipoproteins
Peripheral Arterial Disease
Therapeutics
Apolipoproteins B
Intermittent Claudication
LDL Cholesterol
Myocardial Infarction
Exercise
Lipids

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Gardner, Andrew W. ; Alaupovic, Petar ; Parker, Donald E. ; Montgomery, Polly S. ; Esponda, Omar L. ; Casanegra, Ana I. / Influence of peripheral artery disease and statin therapy on apolipoprotein profiles. In: International Journal of Vascular Medicine. 2013 ; Vol. 2013.
@article{83d514c489ab431eb201e505b939f79f,
title = "Influence of peripheral artery disease and statin therapy on apolipoprotein profiles",
abstract = "Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n=17) or untreated (n=12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P<0.05) and lower values of Lp-A-I:A-II (P<0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P<0.05), Lp-A-II:B:C:D:E (P<0.05), Lp-B:E + Lp-B:C:E (P<0.05), Lp-B:C (P<0.05), and Lp-A-I (P<0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670.",
author = "Gardner, {Andrew W.} and Petar Alaupovic and Parker, {Donald E.} and Montgomery, {Polly S.} and Esponda, {Omar L.} and Casanegra, {Ana I.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1155/2013/548764",
language = "English (US)",
volume = "2013",
journal = "International Journal of Vascular Medicine",
issn = "2090-2824",
publisher = "Hindawi Publishing Corporation",

}

Influence of peripheral artery disease and statin therapy on apolipoprotein profiles. / Gardner, Andrew W.; Alaupovic, Petar; Parker, Donald E.; Montgomery, Polly S.; Esponda, Omar L.; Casanegra, Ana I.

In: International Journal of Vascular Medicine, Vol. 2013, 548764, 01.01.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Influence of peripheral artery disease and statin therapy on apolipoprotein profiles

AU - Gardner, Andrew W.

AU - Alaupovic, Petar

AU - Parker, Donald E.

AU - Montgomery, Polly S.

AU - Esponda, Omar L.

AU - Casanegra, Ana I.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n=17) or untreated (n=12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P<0.05) and lower values of Lp-A-I:A-II (P<0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P<0.05), Lp-A-II:B:C:D:E (P<0.05), Lp-B:E + Lp-B:C:E (P<0.05), Lp-B:C (P<0.05), and Lp-A-I (P<0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670.

AB - Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n=17) or untreated (n=12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P<0.05) and lower values of Lp-A-I:A-II (P<0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P<0.05), Lp-A-II:B:C:D:E (P<0.05), Lp-B:E + Lp-B:C:E (P<0.05), Lp-B:C (P<0.05), and Lp-A-I (P<0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.gov NCT00618670.

UR - http://www.scopus.com/inward/record.url?scp=84884832993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884832993&partnerID=8YFLogxK

U2 - 10.1155/2013/548764

DO - 10.1155/2013/548764

M3 - Article

C2 - 24102029

AN - SCOPUS:84884832993

VL - 2013

JO - International Journal of Vascular Medicine

JF - International Journal of Vascular Medicine

SN - 2090-2824

M1 - 548764

ER -